First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: Results of a phase II study

Oncology

Volumn 55, Issue 5, 1998, Pages 384-390

  Llombart Cussac, Antonio ^a,b   Pivot, Xavier ^a   Rhor Alvarado, Alba ^a   Le Cesne, Axel ^a   Le Chevalier, Thierry ^a   Tursz, Thomas ^a   Spielmann, Marc ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Chemotherapy; Metastatic breast cancer; Mitoxantrone; Vinorelbine

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIRUBICIN; MITOXANTRONE; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; FATIGUE; FEVER; GRANULOCYTOPENIA; HEART FAILURE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0031875374     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011883     Document Type: Article

References (24)

1. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-805.
2. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259.
3. Misset JL, di Palma M, Delgado M, et al: Adjuvant treatment of node positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 1996;14:1136-1145.
4. Carmo-Pereira J, Costa FO, Henriques E, et al: A comparison of two dose levels of adriamycin in the primary treatment of disseminated breast carcinoma. Br J Cancer 1987;56:471-473.
5. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirucibin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996;14:1146-1155.
6. Valagussa P, Tancini G, Bonadonna G: Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986;58: 1411-1417.
7. Kardinal CG, Perry MC, Korzun AH, et al: Response to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. Cancer 1988;61:415-419.
8. Goldhirsch A, Gelber RD, Price KN, et al: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994;343: 377-381.
9. Rubens RD, Bajetta E, Bonneterre J, et al: Treatment of relapse of breast cancer after adjuvant systemic therapy. Review and guidelines for future research. Eur J Cancer 1994; 30A:106-111.
10. Houston SJ, Richards MA, Bentley AE, et al: The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur J Cancer 1993;29A:1513-1518.
11. Bonneterre J, Mercier M: Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. Cancer Treat Rev 1993;19(suppl B): 21-30.
12. Venturini M, Bruzzi P, Del Mastro L, et al: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996;14:764-773.
13. Falkson G, Gelman R, Falkson CI, et al: Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: A prospective Eastern Cooperative Oncology Group study. J Clin Oncol 1991;9:2153-2161.
14. Potier P: The synthesis of Navelbine, prototype of a new series of vinblastine derivates. Semin Oncol 1989;16(suppl 4):2-4.
15. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-1252.
16. Garcia-Conde J, Lluch A, Martin M, et al: Phase II trial of weekly IV Navelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;11:854-857.
17. Spielmann M, Dorval T, Turpin T, et al: Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994;12:1764-1770.
18. Honig SF: Treatment of metastatic disease. Hormonal therapy and chemotherapy; in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Disease of the Breast. Philadelphia, Lippincott-Raven, 1996, pp 669-734.
19. Miller AB, Hoogstraten B, Staquet N, et al: Reporting results of cancer treatment. Cancer 1981;47:207-214.
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Ferrero JM, Pivot X, Namer M, et al: Association mitoxantrone-vinorelbine en première ligne thérapeutique dans le cancer du sein métastatique. Bull Cancer 1995;82:202-207.
22. Dieras V, Extra JM, Bellisant E, et al: Efficacy and tolerance of vinorelbine and fluorouracil combination as first line chemotherapy of advanced breast cancer: Results of a phase II study using a sequential group method. J Clin Oncol 1996;14:3097-3104.
23. Hortobagyi GN: Paclitaxel-based combination chemotherapy for breast cancer. Oncology 1997;11(suppl 2):29-37.
24. Hainsworth JD, Jones SE, Mennel RG, et al: Paclitaxel with mitoxantrone, fluorouracil, and high dose leucovorin in the treatment of metastatic breast cancer: A phase II study. J Clin Oncol 1996;14:1611-1616.